Potential Role of the Endocannabinoid Receptor Antagonist Rimonabant in the Management of Cardiometabolic Risk: A Narrative Review of Available Data

Vascular Health and Risk Management - New Zealand
doi 10.2147/vhrm.2007.3.2.181